Search Within

Hani Hassoun

Formats
  1. Meeting Abstract (232)
  2. Journal Article (90)
  3. Research Letter (9)
  4. Correspondence (4)
  5. Book Section (2)
  6. Review (2)
Groups
  1. Center for Hematologic Malignancies (339)
  2. Department of Medicine (339)
  3. Hematologic Malignancies, Division of (339)
  4. Myeloma (339)
  5. Survivorship Research (253)
  6. Bone Marrow Transplant (241)

More Groups

People
  1. Heather Landau (224)
  2. Sergio Giralt (205)
  3. Alexander Lesokhin (202)
  4. David Chung (166)
  5. Neha Korde (166)
  6. Sham Mailankody (163)

More People

Years
  1. 2025 (7)
  2. 2024 (35)
  3. 2023 (37)
  4. 2022 (36)
  5. 2021 (21)
  6. 2020 (28)

More Years

Publications
  1. Blood (133)
  2. Clinical Lymphoma, Myeloma and Leukemia (51)
  3. Journal of Clinical Oncology (27)
  4. Biology of Blood and Marrow Transplantation (19)
  5. Leukemia and Lymphoma (14)
  6. American Journal of Hematology (10)

More Publications

Publishers
  1. American Society of Hematology (141)
  2. Elsevier Inc. (74)
  3. American Society of Clinical Oncology (27)
  4. Nature Publishing Group (24)
  5. Taylor & Francis Group (21)
  6. John Wiley & Sons, Inc. (10)

More Publishers

Results (339)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed to prior alkylator therapy-subgroup analysis
    Meeting Abstract

    Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in 55 patients (pts) with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)-subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) - health-related quality of life (HRQoL) analysis
    Meeting Abstract

    Oriol, A.; Richardson, P. G.; Mateos, M. V.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)-analysis of adverse events related to hospitalizations
    Meeting Abstract

    Nadeem, O.; Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics-subgroup analysis
    Meeting Abstract

    Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma-age subgroup analysis of elderly patients
    Meeting Abstract

    Larocca, A.; Richardson, P. G.; Oriol, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106) versus MAMMOTH: An indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents
    Meeting Abstract

    Creixenti, J. B.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save